Shenghang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shenghang Zhang has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Shuiliang Wang
Fujian Key Laboratory of Aptamers Technology, Affiliated Dongfang Hospital of School of Medicine, Xiamen University, Fuzhou, P. R. China
4 shared publications Huimin Niu
3 shared publications- Huimin Niu
Fuzong Clinical Medical College of Fujian Medical University
3 shared publications Li Chen
Fujian Key Laboratory of Aptamers Technology 900th Hospital of Joint Logistics Support Force, People's Liberation Army (PLA) Fuzhou Fujian China
3 shared publicationsMeng Zhao
Department of Clinical Laboratory Medicine, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, Fujian, China
3 shared publications- Xi Zhou
West China Hospital, Sichuan University, Jintang Hospital, Jintang First People's Hospital
3 shared publications
Latest Publications
- 1 October 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 315
Serum-compatible screening and truncation optimization of copeptin aptamers for TdT-amplified fluorescent detection
- 1 October 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 315
Serum-compatible screening and truncation optimization of copeptin aptamers for TdT-amplified fluorescent detection
- 1 October 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (10) , 709
Serum-compatible aptamer-regulated RCA–CRISPR/Cas12a assay for fluorescence and lateral flow detection of myeloperoxidase
- 1 October 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (10) , 709
Serum-compatible aptamer-regulated RCA–CRISPR/Cas12a assay for fluorescence and lateral flow detection of myeloperoxidase
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50335
EBV induced Evans syndrome in a patient of SLE related MAS
Rationale: Epstein-Barr virus (EBV) induced Evans syndrome in systemic lupus erythematosus (SLE) related macrophage activation syndrome (MAS) is rare with the incidence rate of 0.9% to 9% and the mortality rate of about 4% to 19%, which are misdiagnosed as hemophagocytic lymphohistiocytosis. Patient concerns: A 15-years old female was admitted due to abdominal pain and fever. Physical examination showed butterfly-shaped erythema on her face and scattered lymph nodes of bilateral neck with a diameter of 1.5 cm × 1.0 cm. Pharyngeal mucosal congestion, bilateral tonsil swelling, and palpable 1 cm below the liver rib and no palpable spleen were observed. Medical history revealed recurrent facial erythema after puberty, which is aggravated by exposure to sunlight. Diagnoses: Based on the results of complete blood cell count, biochemical and immunologic examination and bone marrow cytology, EBV-induced Evans syndrome of SLE-related MAS was reached. Interventions: Ceftriaxone, oseltamivir, methylprednisolone, omeprazole, cyclosporine, and high-dose immunoglobulin were administrated and after 20 days the patient was discharged and regularly followed up. Outcomes: After 20 days of administration, the patient was significantly improved and discharged. Lessons: Disease history, laboratory tests, and differential diagnosis contribute to the confirmation of EBV-induced Evans syndrome in SLE-related MAS.
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50335
Open AccessEBV induced Evans syndrome in a patient of SLE related MAS
Rationale: Epstein-Barr virus (EBV) induced Evans syndrome in systemic lupus erythematosus (SLE) related macrophage activation syndrome (MAS) is rare with the incidence rate of 0.9% to 9% and the mortality rate of about 4% to 19%, which are misdiagnosed as hemophagocytic lymphohistiocytosis. Patient concerns: A 15-years old female was admitted due to abdominal pain and fever. Physical examination showed butterfly-shaped erythema on her face and scattered lymph nodes of bilateral neck with a diameter of 1.5 cm × 1.0 cm. Pharyngeal mucosal congestion, bilateral tonsil swelling, and palpable 1 cm below the liver rib and no palpable spleen were observed. Medical history revealed recurrent facial erythema after puberty, which is aggravated by exposure to sunlight. Diagnoses: Based on the results of complete blood cell count, biochemical and immunologic examination and bone marrow cytology, EBV-induced Evans syndrome of SLE-related MAS was reached. Interventions: Ceftriaxone, oseltamivir, methylprednisolone, omeprazole, cyclosporine, and high-dose immunoglobulin were administrated and after 20 days the patient was discharged and regularly followed up. Outcomes: After 20 days of administration, the patient was significantly improved and discharged. Lessons: Disease history, laboratory tests, and differential diagnosis contribute to the confirmation of EBV-induced Evans syndrome in SLE-related MAS.
- Open Access
- 17 July 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 312, 119037
Flexible wood-derived hydrogel patch for smartphone-assisted interval sweat cortisol profiling
- 17 July 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 312, 119037
Open AccessFlexible wood-derived hydrogel patch for smartphone-assisted interval sweat cortisol profiling
- 7 March 2026
- Published by MyJove Corporation
- No. 229,p. e70758
JoVE Video Dataset
Phosphonic acids are widely used in medicinal chemistry, chemical biology, and materials research. Their preparation can be difficult. Side reactions are common. Purification can be slow. This protocol describes a step-by-step synthesis of (R)-2,3-dihydroxypropylphosphonic acid from a glycerol-derived chiral precursor using an Arbuzov C-P bond-forming step. The route has three stages. First, the alcohol is converted to the corresponding bromide. Next, triethyl phosphite is used to form the phosphonate ester. Finally, deprotection and de-esterification give the free phosphonic acid. The product is then purified to a high level of chemical purity. Reaction progress and product identity are checked by 1H, 13C, and 31P NMR spectroscopy and by high-resolution Liquid Chromatograph-Mass Spectrometer (LC-MS). The method uses common reagents and standard equipment. It is designed for reproducibility and routine use. It will be useful for synthetic and medicinal chemists who need chiral phosphonic acids as building blocks or reference standards.
- 7 March 2026
- Published by MyJove Corporation
- No. 229,p. e70758
JoVE Video Dataset
Phosphonic acids are widely used in medicinal chemistry, chemical biology, and materials research. Their preparation can be difficult. Side reactions are common. Purification can be slow. This protocol describes a step-by-step synthesis of (R)-2,3-dihydroxypropylphosphonic acid from a glycerol-derived chiral precursor using an Arbuzov C-P bond-forming step. The route has three stages. First, the alcohol is converted to the corresponding bromide. Next, triethyl phosphite is used to form the phosphonate ester. Finally, deprotection and de-esterification give the free phosphonic acid. The product is then purified to a high level of chemical purity. Reaction progress and product identity are checked by 1H, 13C, and 31P NMR spectroscopy and by high-resolution Liquid Chromatograph-Mass Spectrometer (LC-MS). The method uses common reagents and standard equipment. It is designed for reproducibility and routine use. It will be useful for synthetic and medicinal chemists who need chiral phosphonic acids as building blocks or reference standards.
- 6 March 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 229,p. e70758
Synthesis of (R)-2,3-Dihydroxypropylphosphonic Acid via an Arbuzov-Based Strategy
Phosphonic acids are widely used in medicinal chemistry, chemical biology, and materials research. Their preparation can be difficult. Side reactions are common. Purification can be slow. This protocol describes a step-by-step synthesis of (R)-2,3-dihydroxypropylphosphonic acid from a glycerol-derived chiral precursor using an Arbuzov C-P bond-forming step. The route has three stages. First, the alcohol is converted to the corresponding bromide. Next, triethyl phosphite is used to form the phosphonate ester. Finally, deprotection and de-esterification give the free phosphonic acid. The product is then purified to a high level of chemical purity. Reaction progress and product identity are checked by 1H, 13C, and 31P NMR spectroscopy and by high-resolution Liquid Chromatograph-Mass Spectrometer (LC-MS). The method uses common reagents and standard equipment. It is designed for reproducibility and routine use. It will be useful for synthetic and medicinal chemists who need chiral phosphonic acids as building blocks or reference standards.
- 6 March 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 229,p. e70758
Synthesis of (R)-2,3-Dihydroxypropylphosphonic Acid via an Arbuzov-Based Strategy
Phosphonic acids are widely used in medicinal chemistry, chemical biology, and materials research. Their preparation can be difficult. Side reactions are common. Purification can be slow. This protocol describes a step-by-step synthesis of (R)-2,3-dihydroxypropylphosphonic acid from a glycerol-derived chiral precursor using an Arbuzov C-P bond-forming step. The route has three stages. First, the alcohol is converted to the corresponding bromide. Next, triethyl phosphite is used to form the phosphonate ester. Finally, deprotection and de-esterification give the free phosphonic acid. The product is then purified to a high level of chemical purity. Reaction progress and product identity are checked by 1H, 13C, and 31P NMR spectroscopy and by high-resolution Liquid Chromatograph-Mass Spectrometer (LC-MS). The method uses common reagents and standard equipment. It is designed for reproducibility and routine use. It will be useful for synthetic and medicinal chemists who need chiral phosphonic acids as building blocks or reference standards.
- Open Access
- 26 January 2026
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (4) , 614-626
Complement–Coagulation Axis and Metabolic Dysregulation Underlie the Transition from Mild to Severe Heat Stroke: A Combined Clinical and Proteomic Study
Background: Heat stroke is a life-threatening condition marked by hyperthermia, central nervous system dysfunction, and multiorgan injury. Exertional heatstroke (EHS) primarily affects healthy young individuals after intense training or heavy labor in hot, humid environments. However, the molecular events driving the progression from mild to severe EHS remain poorly understood. This study integrated clinical data with serum proteomics to identify key pathways and biomarkers involved in EHS progression. Methods: Serum samples were collected from mild EHS patients (n=7), severe EHS patients (n=7), and controls. Demographic data, laboratory results, and Sequential Organ Failure Assessment scores were recorded. Serum proteins were analyzed using label-free mass spectrometry. Comparisons between mild versus control, severe versus control, and severe versus mild groups. Differentially expressed proteins were identified and analyzed using bioinformatics techniques. Enzyme-linked immunosorbent assay was used for further validation. Results: Comparison of clinical data between mild and severe cases exhibited significantly higher markers of inflammation (white blood cell), coagulation abnormalities, organ injury and higher Sequential Organ Failure Assessment scores.Proteomic analysis identified 51 differentiall expressed proteins, highlighting activation of the complement–coagulation axis, nuclear factor kappa–B signaling, metabolic dysregulation, and immune responses. Von Willebrand factor, Mannan-binding lectin serine protease 1, coagulation factor VIII, and vitamin K-dependent protein C exhibited strong discriminative ability and correlated with severity. HSP70/HSP90 levels were elevated in EHS but not severity-dependent. Conclusions: These findings indicate complement- coagalation and metabolic dysregulation drive mild to severe EHS progression, with identified proteins serving as potential biomarkers and therapeutic targets.
- 26 January 2026
- Published by Wolters Kluwer Health in Shock
- Vol. 65 (4) , 614-626
Open AccessComplement–Coagulation Axis and Metabolic Dysregulation Underlie the Transition from Mild to Severe Heat Stroke: A Combined Clinical and Proteomic Study
Background: Heat stroke is a life-threatening condition marked by hyperthermia, central nervous system dysfunction, and multiorgan injury. Exertional heatstroke (EHS) primarily affects healthy young individuals after intense training or heavy labor in hot, humid environments. However, the molecular events driving the progression from mild to severe EHS remain poorly understood. This study integrated clinical data with serum proteomics to identify key pathways and biomarkers involved in EHS progression. Methods: Serum samples were collected from mild EHS patients (n=7), severe EHS patients (n=7), and controls. Demographic data, laboratory results, and Sequential Organ Failure Assessment scores were recorded. Serum proteins were analyzed using label-free mass spectrometry. Comparisons between mild versus control, severe versus control, and severe versus mild groups. Differentially expressed proteins were identified and analyzed using bioinformatics techniques. Enzyme-linked immunosorbent assay was used for further validation. Results: Comparison of clinical data between mild and severe cases exhibited significantly higher markers of inflammation (white blood cell), coagulation abnormalities, organ injury and higher Sequential Organ Failure Assessment scores.Proteomic analysis identified 51 differentiall expressed proteins, highlighting activation of the complement–coagulation axis, nuclear factor kappa–B signaling, metabolic dysregulation, and immune responses. Von Willebrand factor, Mannan-binding lectin serine protease 1, coagulation factor VIII, and vitamin K-dependent protein C exhibited strong discriminative ability and correlated with severity. HSP70/HSP90 levels were elevated in EHS but not severity-dependent. Conclusions: These findings indicate complement- coagalation and metabolic dysregulation drive mild to severe EHS progression, with identified proteins serving as potential biomarkers and therapeutic targets.
- Open Access
- 21 January 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (3) , 1-19
Mangiferin in human disease: Multifaceted mechanisms and applications (Review)
Mangiferin (MGF) is a natural C‑glucosyl xanthone with multitarget activity relevant to metabolic, inflammatory and cancer diseases. Notably, MGF modulates AMP‑activated protein kinase, NF‑κB, PI3K/AKT and MAPK signaling; through these pathways, it affects glucose and lipid metabolism, oxidative stress, apoptosis and inflammatory responses. In metabolic disorders, MGF has been shown to improve insulin sensitivity, support mitochondrial function and reduce diabetic complications. In cancer models, MGF suppresses proliferation, invasion and angiogenesis, and can influence antitumor immunity in the tumor microenvironment. Anti‑inflammatory actions include decreased cytokine release and regulation of the NLR family pyrin domain‑containing 3 inflammasome. Notably, clinical translation remains limited due to its low aqueous solubility, poor oral bioavailability and rapid metabolism. However, benefits of nanocarrier delivery, structural optimization and combination therapy have been reported, which may improve exposure and efficacy in experimental systems. Furthermore, safety signals in animals are favorable at relevant doses, but clinical evidence remains limited. In conclusion, the present review summarizes the pharmacodynamics and mechanisms of MGF across major disease settings and identifies key gaps for translation. Priorities include standardized clinical trials, optimization of delivery strategies, and rigorous assessment of long‑term safety and efficacy.
- 21 January 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (3) , 1-19
Open AccessMangiferin in human disease: Multifaceted mechanisms and applications (Review)
Mangiferin (MGF) is a natural C‑glucosyl xanthone with multitarget activity relevant to metabolic, inflammatory and cancer diseases. Notably, MGF modulates AMP‑activated protein kinase, NF‑κB, PI3K/AKT and MAPK signaling; through these pathways, it affects glucose and lipid metabolism, oxidative stress, apoptosis and inflammatory responses. In metabolic disorders, MGF has been shown to improve insulin sensitivity, support mitochondrial function and reduce diabetic complications. In cancer models, MGF suppresses proliferation, invasion and angiogenesis, and can influence antitumor immunity in the tumor microenvironment. Anti‑inflammatory actions include decreased cytokine release and regulation of the NLR family pyrin domain‑containing 3 inflammasome. Notably, clinical translation remains limited due to its low aqueous solubility, poor oral bioavailability and rapid metabolism. However, benefits of nanocarrier delivery, structural optimization and combination therapy have been reported, which may improve exposure and efficacy in experimental systems. Furthermore, safety signals in animals are favorable at relevant doses, but clinical evidence remains limited. In conclusion, the present review summarizes the pharmacodynamics and mechanisms of MGF across major disease settings and identifies key gaps for translation. Priorities include standardized clinical trials, optimization of delivery strategies, and rigorous assessment of long‑term safety and efficacy.
- 13 January 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1388, 345095
Ultrasensitive electrochemiluminescence aptasensor for heparin-binding protein based on hybridization chain reaction (HCR) amplification and magnetic enrichment
- 13 January 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1388, 345095
Ultrasensitive electrochemiluminescence aptasensor for heparin-binding protein based on hybridization chain reaction (HCR) amplification and magnetic enrichment
- Open Access
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1669811
Rapid identification of Acinetobacter baumannii using novel specific molecular targets derived from pan-genome analysis and its clinical application
Acinetobacter baumannii is a pathogen capable of causing severe hospital-acquired infections such as ventilator-associated pneumonia and bacteremia, accounting for over 80% of nosocomial infections. Current nucleic acid tests (NATs) for A. baumannii suffer from limitations in specificity and sensitivity due to reliance on suboptimal targets. Therefore, this study aimed to identify novel, highly specific molecular targets for A. baumannii NATs using pan-genome analysis. A total of 9 specific molecular targets for A. baumannii were screened from 642 genome sequences by pan-genome analysis: outO, ureE, rplY, bioF, menH_3, hemW, paaF_1, smpB and ppaX . These specific species targets have been verified by BLAST and PCR of non-target strains to have 100% specificity for A. baumannii . The specificity of the 9 target genes was verified by PCR, and 3 pairs of different PCR primers were designed for each target gene to determine the best sensitivity of PCR method for each target. Corresponding qPCR detection methods of 9 targets was also established and that of ureE was screened with the lowest detection limit of 10 −7 ng/μL. The qPCR method based on the ureE gene can achieve rapid, sensitive and accurate detection of A. baumannii in actual samples with interference from non-target bacteria. After verification of 23 samples, the qPCR method based on the mined target met the requirements in sensitivity, specificity and efficiency, and was consistent with the national verification method. These results confirm that novel pan-genome targets with excellent generalizability among A. baumannii strains enhance detection accuracy in hospital environments, bringing hope for rapid clinical identification, timely interventions, and reduced mortality.
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1669811
Open AccessRapid identification of Acinetobacter baumannii using novel specific molecular targets derived from pan-genome analysis and its clinical application
Acinetobacter baumannii is a pathogen capable of causing severe hospital-acquired infections such as ventilator-associated pneumonia and bacteremia, accounting for over 80% of nosocomial infections. Current nucleic acid tests (NATs) for A. baumannii suffer from limitations in specificity and sensitivity due to reliance on suboptimal targets. Therefore, this study aimed to identify novel, highly specific molecular targets for A. baumannii NATs using pan-genome analysis. A total of 9 specific molecular targets for A. baumannii were screened from 642 genome sequences by pan-genome analysis: outO, ureE, rplY, bioF, menH_3, hemW, paaF_1, smpB and ppaX . These specific species targets have been verified by BLAST and PCR of non-target strains to have 100% specificity for A. baumannii . The specificity of the 9 target genes was verified by PCR, and 3 pairs of different PCR primers were designed for each target gene to determine the best sensitivity of PCR method for each target. Corresponding qPCR detection methods of 9 targets was also established and that of ureE was screened with the lowest detection limit of 10 −7 ng/μL. The qPCR method based on the ureE gene can achieve rapid, sensitive and accurate detection of A. baumannii in actual samples with interference from non-target bacteria. After verification of 23 samples, the qPCR method based on the mined target met the requirements in sensitivity, specificity and efficiency, and was consistent with the national verification method. These results confirm that novel pan-genome targets with excellent generalizability among A. baumannii strains enhance detection accuracy in hospital environments, bringing hope for rapid clinical identification, timely interventions, and reduced mortality.